MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
20.36
+0.09 (0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
MBX Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -55.18 | -32.56 | -26.14 |
| Depreciation & Amortization | 0.23 | 0.16 | 0.06 |
| Loss (Gain) From Sale of Assets | 0.07 | 0.07 | - |
| Loss (Gain) From Sale of Investments | -2.13 | -1.04 | -0.03 |
| Stock-Based Compensation | 4.75 | 2.04 | 0.31 |
| Other Operating Activities | 0.1 | 0.1 | 1.39 |
| Change in Accounts Payable | 2.97 | 0.41 | 0.67 |
| Change in Other Net Operating Assets | -0.6 | -1.15 | 0.62 |
| Operating Cash Flow | -49.79 | -31.98 | -23.12 |
| Capital Expenditures | -0.84 | -0.13 | -0.44 |
| Investment in Securities | -121.37 | -30.8 | -10.97 |
| Investing Cash Flow | -122.21 | -30.93 | -11.41 |
| Short-Term Debt Issued | - | - | 10 |
| Total Debt Issued | - | - | 10 |
| Net Debt Issued (Repaid) | - | - | 10 |
| Issuance of Common Stock | 174.77 | 0.74 | 0.03 |
| Other Financing Activities | -4.01 | -0.03 | -0.46 |
| Financing Cash Flow | 234.26 | 69.22 | 46.06 |
| Net Cash Flow | 62.26 | 6.31 | 11.53 |
| Free Cash Flow | -50.63 | -32.11 | -23.56 |
| Free Cash Flow Per Share | -3.68 | -2.62 | -2.94 |
| Levered Free Cash Flow | - | -20.56 | - |
| Unlevered Free Cash Flow | - | -20.56 | - |
| Change in Net Working Capital | - | 0.56 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.